Aldeyra Therapeutics (ALDX) said Tuesday that patient-reported ocular discomfort and itching were "statistically lower" with reproxalap compared with Xiidra in a phase 2 trial in patients with dry eye disease.
In addition, results showed no moderate or serious adverse events related to the drug, with no safety signals observed, the company said.
Aldeyra shares were marginally lower in morning trading.